创伤性脑损伤中的脑组织氧监测第二部分:孤立与合并 insults 与结局的关系
该研究纳入2002至2022年英国剑桥Addenbrooke医院神经重症监护病房收治的239例TBI患者,均具备GOS临床结局数据及至少12小时的ICP和pbtO2监测。结局二分为预后良好/不良(GOS 4-5/1-3)和生存/死亡(GOS 2-5/1)。pbtO2中位数与结局仅有轻微、无统计学显著关联;pbtO2阈值25和20 mmHg在预后良好/不良及死亡/生存的卡方分析中分别给出最高χ²。pbtO2低于25 mmHg的时间百分比越高、剂量越大及阈值越低与预后不良相关,但与死亡率无关。pbtO2低于15 mmHg的时间百分比越高,预后不良率越高(多因素logistic回归)。
要点
- 239例TBI患者中,pbtO2中位数与结局仅轻微相关但未达统计学显著。
- pbtO2阈值25和20 mmHg在预后良好/不良及死亡/生存的卡方分析中分别给出最高χ²。
- pbtO2低于25 mmHg的时间百分比越高、剂量越大及阈值越低与预后不良相关,但与死亡率无关。
- pbtO2低于25-30 mmHg持续30分钟时结局由良好转向不良,强度更高时更短时间即可出现类似转变。
- pbtO2<15 mmHg时间百分比越高,预后不良率越高(多因素logistic回归),且合并ICP>20 mmHg、CPP<60 mmHg或PRx>0.30时关联更强。
适用人群与场景
- 2002至2022年在英国剑桥Addenbrooke医院神经重症监护病房治疗的TBI患者,共239例,具备GOS临床结局数据及至少12小时的ICP和pbtO2监测。
诊断标准与关键阈值
- 结局二分为预后良好/不良(GOS 4-5/1-3)和生存/死亡(GOS 2-5/1)。
- pbtO2阈值25和20 mmHg在预后良好/不良及死亡/生存的卡方分析中分别给出最高χ²。
- pbtO2低于25-30 mmHg持续30分钟时结局由良好转向不良;强度更高时更短持续时间即可出现类似转变。
- pbtO2低于15 mmHg时,若同时ICP>20 mmHg、CPP<60 mmHg或PRx>0.30,与预后不良的关联强于这些变量未紊乱时。
红旗征与不能漏的情况
- pbtO2低于15 mmHg且合并ICP>20 mmHg、CPP<60 mmHg或PRx>0.30时,与预后不良的关联更强。
- pbtO2低于25 mmHg的时间百分比越高、剂量越大及阈值越低与预后不良相关。
研究设计与关键结果
- 研究类型为单中心队列,纳入239例TBI患者,pbtO2中位数与结局仅轻微相关但未达统计学显著。
- pbtO2阈值25和20 mmHg在预后良好/不良及死亡/生存的卡方分析中分别给出最高χ²。
- pbtO2低于25 mmHg的时间百分比越高、剂量越大及阈值越低与预后不良相关,但与死亡率无关。
- pbtO2低于25-30 mmHg持续30分钟时结局由良好转向不良,强度更高时更短持续时间即可出现类似转变。
- pbtO2低于15 mmHg时,若同时ICP>20 mmHg、CPP<60 mmHg或PRx>0.30,与预后不良的关联强于这些变量未紊乱时。
- 多因素logistic回归显示,pbtO2<15 mmHg的监测时间百分比越高,预后不良率越高。
证据类型、等级与局限
- 证据类型:单中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为低pbtO2(低于25 mmHg,尤其低于15 mmHg)持续时间较长且合并整体脑生理变量紊乱与不良结局相关,可能提示有害的缺血性缺氧。
- 作者认为需要前瞻性试验来确定pbtO2导向治疗是否有益、个体化pbtO2阈值以及如何取决于合并脑生理紊乱的存在与否。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The primary aim was to explore the concept of isolated and combined threshold-insults for brain tissue oxygenation (pbtO2) in relation to outcome in traumatic brain injury (TBI).
METHODS: A total of 239 TBI patients with data on clinical outcome (GOS) and intracranial pressure (ICP) and pbtO2 monitoring for at least 12 h, who had been treated at the neurocritical care unit, Addenbrooke's Hospital, Cambridge, UK, between 2002 and 2022 were included. Outcome was dichotomised into favourable/unfavourable (GOS 4-5/1-3) and survival/mortality (GOS 2-5/1). PbtO2 was studied over the entire monitoring period. Thresholds were analysed in relation to outcome based on median and mean values, percentage of time and dose per hour below critical values and visualised as the combined insult intensity and duration.
RESULTS: Median pbtO2 was slightly, but not significantly, associated with outcome. A pbtO2 threshold at 25 and 20 mmHg, respectively, yielded the highest x2 when dichotomised for favourable/unfavourable outcome and mortality/survival in chi-square analyses. A higher dose and higher percentage of time spent with pbtO2 below 25 mmHg as well as lower thresholds were associated with unfavourable outcome, but not mortality. In a combined insult intensity and duration analysis, there was a transition from favourable towards unfavourable outcome when pbtO2 went below 25-30 mmHg for 30 min and similar transitions occurred for shorter durations when the intensity was higher. Although these insults were rare, pbtO2 under 15 mmHg was more strongly associated with unfavourable outcome if, concurrently, ICP was above 20 mmHg, cerebral perfusion pressure below 60 mmHg, or pressure reactivity index above 0.30 than if these variables were not deranged. In a multiple logistic regression, a higher percentage of monitoring time with pbtO2 < 15 mmHg was associated with a higher rate of unfavourable outcome.
CONCLUSIONS: Low pbtO2, under 25 mmHg and particularly below 15 mmHg, for longer durations and in combination with disturbances in global cerebral physiological variables were associated with poor outcome and may indicate detrimental ischaemic hypoxia. Prospective trials are needed to determine if pbtO2-directed therapy is beneficial, at what individualised pbtO2 threshold therapies are warranted, and how this may depend on the presence/absence of concurrent cerebral physiological disturbances.
参考来源
- Svedung Wettervik T, Beqiri E, Hånell A, et al. Brain tissue oxygen monitoring in traumatic brain injury-part II: isolated and combined insults in relation to outcome. Crit Care. 2023. PMID: 37752602. doi:10.1186/s13054-023-04659-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。